Fulgent Genetics (NASDAQ:FLGT) and ELEKTA AB/ADR (OTCMKTS:EKTAY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.
Risk & Volatility
Fulgent Genetics has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, ELEKTA AB/ADR has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500.
Institutional and Insider Ownership
8.1% of Fulgent Genetics shares are held by institutional investors. Comparatively, 0.1% of ELEKTA AB/ADR shares are held by institutional investors. 58.8% of Fulgent Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Fulgent Genetics and ELEKTA AB/ADR’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Fulgent Genetics||$18.73 million||3.93||-$2.51 million||($0.11)||-37.18|
|ELEKTA AB/ADR||$1.37 billion||3.22||$132.53 million||$0.35||34.16|
ELEKTA AB/ADR has higher revenue and earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than ELEKTA AB/ADR, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent recommendations and price targets for Fulgent Genetics and ELEKTA AB/ADR, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Fulgent Genetics presently has a consensus price target of $5.05, suggesting a potential upside of 23.47%. Given Fulgent Genetics’ stronger consensus rating and higher possible upside, analysts plainly believe Fulgent Genetics is more favorable than ELEKTA AB/ADR.
This table compares Fulgent Genetics and ELEKTA AB/ADR’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
ELEKTA AB/ADR pays an annual dividend of $0.05 per share and has a dividend yield of 0.4%. Fulgent Genetics does not pay a dividend. ELEKTA AB/ADR pays out 14.3% of its earnings in the form of a dividend.
Fulgent Genetics Company Profile
Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, Canada, the People's Republic of China, and internationally. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
ELEKTA AB/ADR Company Profile
Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT. It also provides personalized imaging tools; automation and integration systems; beam shaping solutions; patient positioning and immobilization solutions; and radiotherapy treatment planning systems. In addition, the company offers radiosurgery systems under the Leksell Gamma Knife Icon, Leksell Gamma Knife Perfexion, and Elekta Axesse names; Leksell GammaPlan, a treatment planning software; and Elekta Unity, a magnetic resonance radiation therapy solution. Further, it provides care management software, such as MOSAIQ Radiation Oncology and MOSAIQ Medical Oncology; MOSAIQ IQ Scripts, a workflow automation and customization tool; Patient Engagement, a patient communication tool; MOSAIQ Evaluate, a plan management and dose review solution; MOSAIQ Locate, a stereotactic localization solution; and METRIQ, a cancer registry data management solution. Additionally, the company offers Flexitron, a remote after loading platform; microSelectron, a digital pulsed dose rate platform; Esteya, an electronic brachytherapy for treating skin cancer; Oncentra Brachy, a treatment planning software; real-time prostate solutions; and gynecological brachytherapy, bronchus and esophagus, breast, prostate, rectum and bladder, and skin applicators, as well as brachytherapy needles and flexible implant tubes. It also provides Leksell Vantage Stereotactic System for neuroimaging and treatment; Elekta Neuromag TRIUX, a magnetoencephalography system; Leksell Stereotactic System for minimally invasive stereotactic neurosurgery; and proton therapy components. The company was founded in 1972 and is headquartered in Stockholm, Sweden.
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.